Agilent Technologies (A) Stock Rating Reaffirmed by Barclays
Barclays reiterated their buy rating on shares of Agilent Technologies (NYSE:A) in a research report released on Monday morning. Barclays currently has a $74.00 price objective on the medical research company’s stock.
Other research analysts have also issued research reports about the stock. Morgan Stanley reissued an overweight rating on shares of Agilent Technologies in a research note on Tuesday, November 14th. Deutsche Bank set a $75.00 price objective on shares of Agilent Technologies and gave the company a buy rating in a research note on Tuesday, November 21st. Goldman Sachs Group reissued a neutral rating and issued a $68.00 price objective on shares of Agilent Technologies in a research note on Tuesday, September 26th. Cowen reissued a hold rating and issued a $70.00 price objective on shares of Agilent Technologies in a research note on Wednesday, November 22nd. Finally, JPMorgan Chase & Co. raised their target price on shares of Agilent Technologies to $75.00 and gave the company an overweight rating in a report on Tuesday, November 21st. Six equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Agilent Technologies presently has an average rating of Buy and an average target price of $68.98.
Agilent Technologies (NYSE:A) traded up $0.01 during midday trading on Monday, hitting $70.80. 1,511,100 shares of the stock traded hands, compared to its average volume of 1,919,925. The company has a current ratio of 3.30, a quick ratio of 2.85 and a debt-to-equity ratio of 0.37. Agilent Technologies has a twelve month low of $47.05 and a twelve month high of $72.33. The stock has a market capitalization of $22,790.00, a price-to-earnings ratio of 33.88, a price-to-earnings-growth ratio of 2.11 and a beta of 1.28.
Agilent Technologies (NYSE:A) last posted its quarterly earnings data on Monday, November 20th. The medical research company reported $0.67 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.62 by $0.05. Agilent Technologies had a net margin of 15.30% and a return on equity of 16.95%. The business had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. During the same quarter last year, the firm posted $0.59 earnings per share. The business’s revenue for the quarter was up 7.0% compared to the same quarter last year. analysts forecast that Agilent Technologies will post 2.58 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 24th. Investors of record on Tuesday, January 2nd will be issued a $0.149 dividend. This is a boost from Agilent Technologies’s previous quarterly dividend of $0.13. The ex-dividend date of this dividend is Friday, December 29th. This represents a $0.60 annualized dividend and a yield of 0.84%. Agilent Technologies’s dividend payout ratio (DPR) is 28.71%.
In other Agilent Technologies news, CEO Michael R. Mcmullen sold 43,703 shares of the firm’s stock in a transaction that occurred on Friday, January 5th. The shares were sold at an average price of $70.00, for a total transaction of $3,059,210.00. Following the sale, the chief executive officer now owns 302,837 shares of the company’s stock, valued at $21,198,590. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Michael R. Mcmullen sold 22,481 shares of the firm’s stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $68.77, for a total transaction of $1,546,018.37. Following the sale, the chief executive officer now directly owns 336,637 shares in the company, valued at approximately $23,150,526.49. The disclosure for this sale can be found here. In the last ninety days, insiders sold 176,291 shares of company stock worth $12,245,920.
A number of hedge funds have recently added to or reduced their stakes in the business. New England Research & Management Inc. raised its holdings in Agilent Technologies by 79.2% during the fourth quarter. New England Research & Management Inc. now owns 11,650 shares of the medical research company’s stock worth $780,000 after purchasing an additional 5,150 shares in the last quarter. Parametric Portfolio Associates LLC raised its holdings in Agilent Technologies by 9.4% during the third quarter. Parametric Portfolio Associates LLC now owns 616,303 shares of the medical research company’s stock worth $39,567,000 after purchasing an additional 52,920 shares in the last quarter. Steward Partners Investment Advisory LLC acquired a new stake in Agilent Technologies during the third quarter worth approximately $213,000. Public Employees Retirement System of Ohio raised its holdings in Agilent Technologies by 0.9% during the third quarter. Public Employees Retirement System of Ohio now owns 394,744 shares of the medical research company’s stock worth $25,343,000 after purchasing an additional 3,452 shares in the last quarter. Finally, Coastline Trust Co raised its holdings in Agilent Technologies by 20.1% during the third quarter. Coastline Trust Co now owns 10,280 shares of the medical research company’s stock worth $660,000 after purchasing an additional 1,720 shares in the last quarter.
ILLEGAL ACTIVITY NOTICE: This piece of content was published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.dailypolitical.com/2018/01/12/agilent-technologies-a-stock-rating-reaffirmed-by-barclays.html.
Agilent Technologies Company Profile
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.